Dr Thomas Bachelot
- Spécialité
- Oncologue médical, expert sein et gynécologie
- Titre
- Coordinateur adjoint de département
- Hôpital
- Centre Léon Bérard (Lyon)
- Derniers articles
-
- PELICAN-IPC 2015-016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. (31 oct. 2026)
- Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort. (13 oct. 2026)
- Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. (1 oct. 2026)
- Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. (29 sept. 2026)
- Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database. (27 sept. 2026)